Archives
-
Circular IL-23 mRNA and MSA-2-Pt in Tumor Immunotherapy
2026-10-08
He et al. describe a preclinical combination strategy pairing lipid nanoparticles carrying circular IL-23 mRNA with platinum-modified MSA-2, a STING agonist. In a B16F10 melanoma model, the combination was associated with tumor suppression, immune activation, and prolonged survival, while remaining subject to the limitations of a localized, single-model animal study.
-
Dabigatran Et Exilate: Oral Direct Thrombin Inhibition
2026-10-07
This 2011 clinical review describes dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its prodrug design, rapid and predictable anticoagulant effects, and limited dependence on metabolic monitoring. Its most important interpretive finding is that dabigatran etexilate conversion and active dabigatran metabolism do not involve the cytochrome P450 system, although renal function and bleeding risk remain central clinical considerations.
-
Natural Product Library: From Hits to Hypotheses
2026-10-07
DiscoveryProbe Natural Product Library Plus can support a more rigorous path from chemical hits to biological hypotheses. This article interprets the Cryptosporidium AdhE study, clarifies evidence boundaries, and presents a non-operational framework for linking target, phenotype, and mechanism.
-
Imatinib (STI571): Kinase Biology and Assay Context
2026-10-06
Imatinib (STI571) is a selective inhibitor of ABL, c-Kit, and PDGF receptor signaling. Its benchmark activity is biologically informative but assay-dependent, while gastric cancer assembloid research shows why stromal context can alter drug-response interpretation.
-
GSK621 and AMPK Signaling in Cancer Research
2026-10-06
GSK621 is a research compound described by APExBIO as an AMPK agonist, while recent work in Immunity identifies lysosomal 25-hydroxycholesterol, AMPKα, and STAT6 as a regulatory axis in immunosuppressive tumor-associated macrophages. The findings support AMPK as an important mechanistic node, but they do not establish that GSK621 reproduces the full CH25H–25-hydroxycholesterol pathway or demonstrate clinical utility.
-
tFUS, Nespas/miR-383-3p, and SHP2 After Stroke
2026-10-05
A 2025 International Immunopharmacology study links low-intensity transcranial focused ultrasound with reduced post-ischemic NLRP3 neuroinflammation through the Nespas/miR-383-3p/SHP2 pathway. Its combination of a transient MCAO rat model, BV2 microglial experiments, transcriptomic analysis, and pathway perturbation strengthens the mechanistic interpretation while leaving important questions about human translation and treatment generalizability.
-
NSC 87877 and SHP2 Signaling: Evidence, Limits
2026-10-05
NSC 87877 is a potent Shp2 inhibitor for dissecting phosphatase signaling, but its dual Shp1 activity matters when interpreting neuroinflammation data. This article connects the compound’s biochemical profile with the Nespas/miR-383-3p/SHP2 stroke study while defining evidence gaps and translational limits.
-
Five Questions About Fast Green qPCR Evidence
2026-10-04
A source-grounded overview of HotStart Universal 2X FAST Green qPCR Master Mix, explaining qPCR principles, evidence quality, interpretation of the albiflorin RCC study, and important scope limitations.
-
CXCR4–EGFR Heteromers: Signaling and Conformation
2026-10-03
Comez et al. report that CXCR4 and EGFR can assemble into oligomeric signaling complexes whose conformational state and coupling to Gi proteins, PLCγ, and β-arrestin-2 vary with receptor activation. By combining NanoBRET with nanobody-based proximity ligation in engineered and native cells, the study provides a framework for interpreting receptor co-expression as a determinant of EGFR and chemokine signaling rather than as a simple sum of independent pathways.
-
L-NAME Hydrochloride: Decoding NO Vascular Signaling
2026-10-02
L-NAME Hydrochloride, also known as NG-nitro-L-arginine methyl ester, is more than a generic NOS inhibitor. This article explains how to use it as a causal probe for distinguishing nitric oxide signaling from prostaglandin- and receptor-mediated vascular responses.
-
Bedaquiline and Host-Directed TB Assays
2026-10-01
Bedaquiline is a diarylquinoline antibiotic whose bacterial energy-targeting mechanism can be studied alongside host-directed tuberculosis strategies. This article translates recent GSK3 research into practical assay decisions spanning intracellular infection, bacterial persistence, and cancer metabolism.
-
CCK-8 for Cell Viability and Melanoma Research
2026-10-01
Cell Counting Kit-8 (CCK-8) is a WST-8-based colorimetric assay for measuring viable-cell metabolic activity, proliferation, and cytotoxicity in vitro. Its water-soluble formazan product supports direct microplate reading without a solubilization step, making cck8 useful in cancer research and cell-based screening.
-
Torin2: Selective mTOR Inhibitor for Cancer Research
2026-09-30
Torin2 is a potent mTOR inhibitor with a supplier-reported EC50 of 0.25 nM and oral availability. Its documented binding contacts, cellular selectivity, tissue exposure, and activity in medullary thyroid carcinoma models support its use in cancer research, while assay and translation limits require careful interpretation.
-
HOXC8, Caspase-1, and Pyroptosis in Lung Cancer
2026-09-30
The reference study shows that HOXC8 suppresses pyroptotic death in non-small cell lung carcinoma by recruiting HDAC1/2 to repress CASP1 transcription. Its experiments connect a tumor-associated transcription factor with an ASC-independent, caspase-1-dependent cell-death mechanism and suggest that HOXC8 depletion can restrain tumorigenesis.
-
5-Azacytidine: Mechanism, Evidence & Limits
2026-09-29
5-Azacytidine, also called 5-AzaC, is a cytosine analogue and DNA methyltransferase inhibitor used in epigenetic and cancer research. Its established mechanism involves DNMT trapping and methylation remodeling, while recent preclinical evidence links AZA-containing combinations to cancer-cell dormancy and reduced metastatic outgrowth.